RE:RE:RE:CD8+ TiLs and T-cell exhaustionIovance Biotherapeutics' Febrursy 2024 approval of its tumor infiltrating lymphocyte (TIL) therapy serves to confirm ONCY's pelareorep critical effect on the increase of CD8+ TiLs cells as significant mediators of cytotoxic effector function in the treatment of cancer,